Biomoneta Research Private Limited

Biomoneta is an innovation-led healthcare company founded in 2014 in Bengaluru, India, with a mission to redefine infection prevention and control through advanced air decontamination solutions. As a C-CAMP portfolio company, Biomoneta is supported by institutions that recognise the importance of proactive healthcare, addressing infections before symptoms appear rather than after they spread. The company’s vision is to make clinically safe air a global standard, ensuring healthier environments across hospitals, laboratories, workspaces, and homes.

At the heart of Biomoneta’s innovation is ZeBox, its flagship technology and the first India-developed, globally validated advanced air decontamination system. ZeBox is designed to kill a broad spectrum of airborne pathogens, including drug-resistant organisms, while operating safely around people with zero downtime. Unlike conventional air purification systems, ZeBox requires minimal maintenance and delivers continuous protection, making it a breakthrough solution for infection control in high-risk environments. By focusing on prevention at the source, Biomoneta is setting new benchmarks in healthcare innovation.

The company is driven by a team of scientists, engineers, and entrepreneurs united by a passion for clean air and a commitment to making life impossible for airborne pathogens. Its leadership includes Janani Venkatraman (Co-founder & Director), Santanu Datta (Co-founder & Director), Arindam Ghatak (Co-founder & CEO), and Sujit Kumar Biswas (Head – Engineering), each bringing decades of expertise in molecular biology, biophysics, drug discovery, and engineering. Supporting them is a dedicated core execution team comprising Sujith R, Kamal Prakash, Kumar R, Akarsh, and Tanbir Alam, who ensure the company’s vision is translated into impactful solutions.

Biomoneta’s positioning in the healthcare sector is unique, it is not merely a company creating devices, but a pioneer in preventive healthcare innovation. By combining cutting-edge science with practical engineering, Biomoneta is addressing one of the most pressing challenges of modern medicine: the rise of drug-resistant infections. Its solutions are designed to be scalable, safe, and globally relevant, making the company a strong contender in the international healthcare innovation landscape.